Colorectal cancer (CRC) is really a leading reason for tumor-related morbidity and mortality worldwide, with mortality most frequently due to metastatic disease. Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, includes a significant role in treating metastatic CRC (mCRC). However, patient use of bevacizumab might be limited in certain regions or conditions, because of factors associated with insurance policy, reimbursement, patient out-of-pocket costs, or availability. Consequently, outcomes for patients with mCRC might be worsened. Furthermore, counterfeit bevacizumab has infiltrated legitimate supply chains, exposing patients to risk. Oncologists can also be affected detrimentally, since resolving access issues could be time-consuming and demoralizing. The imminent expiry of patents protecting bevacizumab provides other manufacturers using the chance to create highly similar versions referred to as biosimilars. High-quality, safe, and efficient biosimilars have the possibility to grow use of bevacizumab. The majority of the bevacizumab biosimilars presently in development have been in numerous studies in patients with non-small-cell cancer of the lung, and future authorization for mCRC indications will, therefore, depend on extrapolation. This short article looks at the current role of bevacizumab in the treating of mCRC, the potential barriers connected with reduced use of bevacizumab, and also the potential bevacizumab biosimilars in development. How biosimilars may impact treating mCRC can also be discussed.